UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported):
September 1, 2015
CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified
in its charter)
Delaware |
001-34566 |
75-2308816 |
(State or other jurisdiction of |
(Commission File No.) |
(IRS Employer ID No.) |
incorporation or organization) |
|
|
18th Floor, Jialong International Building |
19 Chaoyang Park Road |
Chaoyang District, Beijing 100125 |
People’s Republic of China |
(Address of Principal Executive Offices)
86-10-6698-3166
Registrant's telephone number, including
area code
(Former name or former
address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e
-4(c)) |
Item
8.01 Other Events.
On September 8, 2015, China Biologic Products,
Inc. (the “Company”) issued a press release announcing that its majority-owned subsidiary, Shandong Taibang Biological
Products Co. Ltd., received on September 1, 2015 the approval from the Shandong Provincial Health and Family Planning Commission
to build a new branch collection facility in Shandong Province, China, which will operate under the Company’s Ningyang plasma
collection station. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by
reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit Number |
|
Description |
99.1 |
|
Press release issued by the Company dated September 8, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 8, 2015 |
CHINA BIOLOGIC PRODUCTS, INC. |
|
|
|
|
By: |
/s/ David (Xiaoying) Gao |
|
|
David (Xiaoying) Gao |
|
|
Chief Executive Officer |
Exhibit 99.1
![](tex99-1pg1.jpg)
FOR RELEASE September 8, 2015
China Biologic to Build New Branch Collection
Facility in Shandong Province
BEIJING, China – September 8,
2015 – China Biologic Products, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading
fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary Shandong Taibang
Biological Products Co. Ltd. (“Shandong Taibang”) received approval from the Shandong Provincial Health and Family
Planning Commission on September 1, 2015 to build a new branch collection facility in Shandong Province, which will operate under
the Company’s Ningyang plasma collection station.
This new plasma collection facility,
located in Shanting District of Zaozhuang City, will be a branch of the existing Ningyang plasma collection station, which
was established in July 2011. The new collection facility will cover the collection territory of Zaozhuang City,
which has a population of 3.8 million and offers a reliable source of plasma donors. As the Company had already
completed most of the preparation required for this new facility while awaiting final approval, the new collection facility
is expected to commence operation and collection of source plasma by the end of 2015. The Company expects that the new
facility will reach its designed annual collection capacity within three years thereafter, which will increase the
Company’s total collection capacity by approximately 5-8%.
Mr. David (Xiaoying) Gao, Chairman and
Chief Executive Officer of China Biologic, commented, “The approval of a new collection facility in Shandong represents meaningful
progress in our endeavor to sustainably grow our plasma collection volume. We have a significant market presence in Shandong Province,
which has a total population of 96 million. This new branch collection facility will operate in addition to our existing eight
plasma collection stations in this Province. We will continue to devote our efforts to growing our plasma collection volume at
our existing stations as well as building new collection facilities in strategic locations to maximize the utilization of our processing
capabilities.”
“Additionally, construction of our
two new stations in Hebei Province is on track. We expect to complete the construction of the station in Xinglong County and receive
the necessary government approval to begin operations by the end of this year. We expect to complete construction on the Daming
County station in early 2016 and be able to begin operations within the first half of 2016. With the continued expansion of our
plasma collection capacity and the advancement of our product pipeline, we believe we are well positioned to meet the increasing
market demands for plasma protein therapeutics in China in the coming years,” Mr. Gao concluded.
About China Biologic Products, Inc.
China Biologic is a leading plasma-based
biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the
prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in
Beijing and manufactures over 20 different dosages of plasma-based products through its indirect majority-owned subsidiaries, Shandong
Taibang Biological Products Co., Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment
in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and inoculation centers, as well as distributors,
in China. For additional information, please see the Company's website, www.chinabiologic.com.
Safe Harbor Statement
This news release may contain certain “forward-looking
statements” relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements
of historical fact included herein, are “forward-looking statements.” These forward-looking statements are often identified
by the use of forward-looking terminology such as “believe,” “expect,” “are expected to,” or
similar expressions, and involve known and unknown risks and uncertainties. Among other things, the Company’s plan regarding
the construction of the collection stations, the time required for the collection stations to reach their designed capacities and
quotations from management in this news release contain forward-looking statements. Although the Company believes that the expectations
reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations
may prove to be incorrect.
Investors should not place undue reliance
on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could
differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including, without
limitation potential delay or failure to complete construction of new collection facilities, potential inability to pass government
inspection and certification process for new collection facilities, potential inability to achieve the designed collection capacities
at the new collection facilities, potential inability to achieve the expected operating and financial performance, potential inability
to find alternative sources of plasma, potential inability to increase production at permitted sites, potential inability to mitigate
the financial consequences of a temporarily reduced raw plasma supply through cost cutting or other efficiencies, and potential
additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company’s
periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov).
All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety
by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking
statements.
Contact:
China Biologic Products, Inc.
Mr. Ming Yin
Senior Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com
ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: bill.zima@icrinc.com
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024